Taylor, D. Lansing, PhD

Director, University of Pittsburgh Drug Discovery Institute, Allegheny Foundation Professor of Computational and Systems Biology

Taylor, D. Lansing, PhD

dltaylor@pitt.edu

Office: BST W952
Phone: 412-648-9315
Fax:

Computational & Systems Biology

Biosketch

University of Maryland BS 05/1968 Zoology
State University of New York at Albany PHD 05/1973 Cell Biology
Woods Hole Marine Biology Laboratory Postdoctoral Fellow 1974 Biophysics

I began my academic career as an Assistant Professor at Harvard University and remained at Harvard until 1982, developing and using novel fluorescence-based reagents and imaging technologies to investigate fundamental cellular processes such as cell movements and cell division. I then moved to Carnegie Mellon University as a Professor of Biological Sciences and as Director of the Center for Fluorescence Research in the Biomedical Sciences. In 1991, I became the Director of the National Science Foundation-funded Center for Light Microscope Imaging and Biotechnology, and in 1995, I was named Vice Dean of CMU’s Division of Molecular Sciences. I continued to develop reagent and imaging technologies, while applying the technologies to understand fundamental processes in cells and tissues. Alan Waggoner and I co-founded Biological Detection Systems (BDS) to commercialize the multi-color cyanine dyes and research imaging platforms and it was acquired by Amersham-now GE Life Sciences. I left CMU in 1997 to found Cellomics, Inc., the company that developed High Content Screening (HCS). HCS was the foundation for a shift from focusing primarily on generating images to generating large-scale, quantitative image-based data from cells, tissues and small organisms. I was CEO of this company from 1997 through 2003 when it became part of ThermoFisher. I then founded a third company, Cellumen, that developed a predictive safety assessment platform using primary hepatocytes, multiplexed panels of reagents, reference safety databases and computational biology. I was CEO of Cellumen from 2004 until 2010 when it became part of Cyprotex, a British CRO. I also co-founded Cernostics, Inc., a fluorescence-based, tissue systems pathology company that has created a test for selecting at risk Barrett’s esophagus patients. I hold >25 U.S. patents, including six focused on cell-based imaging. I returned to academia at the end of 2010 to continue my academic interests that now link large-scale cell, tissue and human, biomimetic, tissue-engineered model profiling with computational and systems biology to optimize drug discovery and diagnostics based on quantitative systems pharmacology. I am also developing computational tools to identify and quantify heterogeneity.

  1. Liver metastases: Microenvironments and ex-vivo models. Clark AM, Ma B, Taylor DL, Griffith L, Wells A. Exp Biol Med (Maywood). 2016 Jul 6. pii: 1535370216658144. [Epub ahead of print] PMID: 27390264
  2. Proteomic screening and lasso regression reveal differential signaling in insulin and insulin-like growth factor I pathways. Erdem C, Nagle AM, Casa AJ, Litzenburger BC, Wang YF, Taylor DL, Lee AV, Lezon TR. Mol Cell Proteomics. 2016 Jun 30. pii: mcp.M115.057729. [Epub ahead of print] PMID: 27364358
  3. A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. Stern AM, Schurdak ME, Bahar I, Berg JM, Taylor DL. J Biomol Screen. 2016 Jul;21(6):521-34. doi: 10.1177/1087057116635818. Epub 2016 Mar 8. PMID: 26962875
  4. A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens. Gough A, Shun TY, Taylor DL, Schurdak M. Methods. 2016 Mar 1;96:12-26. doi: 10.1016/j.ymeth.2015.10.007. Epub 2015 Nov 4. PMID: 26476369
  5. TissueCypher(™): A systems biology approach to anatomic pathology. Prichard JW, Davison JM, Campbell BB, Repa KA, Reese LM, Nguyen XM, Li J, Foxwell T, Taylor DL, Critchley-Thorne RJ. J Pathol Inform. 2015 Aug 31;6:48. doi: 10.4103/2153-3539.163987. eCollection 2015. PMID: 26430536